The Airwave Health Monitoring study

What is it and what does it include?

The Airwave Health Monitoring Study was established in 2004 to investigate possible long-term health effects associated with use of TETRA, the radio system used by the police service in Great Britain since 2001. It is a long-term observational study following up the health of the police force with respect to TETRA exposure, and ability to monitor both cancer and non-cancer health outcomes. Baseline screening consisted of an enrolment questionnaire and a health screening. A total of 55,000 participants completed the enrollment questionnaire, of which 46,000 also completed the health screening.

Has this dataset helped researchers understand Alzheimer’s and other dementias better?

Of course!

• AD & Multi-omics:

In 2022, researchers performed a metabolome-wide association study (MWAS) of the blood plasma metabolome for AD risk loci carriers using nuclear magnetic resonance (NMR) spectra of blood from 3258 individuals from the Airwave Health Monitoring Study (Airwave) to investigate the relationship between the human blood metabolome and AD risk. Their results highlight the suitability of integrating multi-omics data into GSMNs to identify metabolic alterations in AD. Furthermore, more than 70% of 298 SNP-metabolite associations in an MWAS corresponded to lipid species, thus validating the presence of lipidomic dysregulation in AD. November 2022  – DOI: https://doi.org/10.1111/jnc.15719

• AD & Metabolomics:

In 2020, investigators developed a model of age based on untargeted metabolic profiling across multiple platforms, including nuclear magnetic resonance spectroscopy and liquid chromatography–mass spectrometry in urine and serum, using data from the UK Airwave cohort to investigate the determinants of accelerated aging, including lifestyle and psychological risk factors for premature mortality. Their results showed that increased metabolomic age acceleration (mAA) was associated after false discovery rate (FDR) correction with overweight/obesity, diabetes, heavy alcohol use and depression. DNA methylation age acceleration measures were uncorrelated with mAA. Furthermore, increased DNA methylation phenotypic age acceleration was associated after FDR correction with heavy alcohol use, hypertension and low income. In conclusion, metabolomics is a promising approach for the assessment of biological age and appears complementary to established epigenetic clocks. June 2020. DOI: 10.1111/acel.13149

Manuscripts citing this dataset

• These are publications from scientific journals which have resulted or benefited from the data or samples collected by the Airwave Study: publications.

Request access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the DPUK team. Once your access has been provisioned, you will receive an email with instructions for federated access including a link to access your API token. For a quick explanation on what is federated data and how to access it, see this video.

Data Use Agreement

Visit the user guides here.

Publishing results using this dataset?

 For detailed information on how to cite ELSA’s data, visit their citation guide here.

Discuss

Post a question or thought about this dataset here.

A blood based 12-miRNA signature of Alzheimer patients - GSE46579 

We applied Next-Generation Sequencing (NGS) to miRNAs from blood samples of 48 AD (Alzheimer's Disease) patients and 22 unaffected controls, yielding a total of 140 unique mature miRNAs with significantly changed expression level. Of these, 82 were higher and 58 lower abundant in samples from AD patients. We selected a panel of 12 miRNAs for a qRT-PCR analysis on a larger cohort of 202 samples including not only AD patients and healthy controls but also patients with other CNS illnesses: Multiple Sclerosis, Parkinson's Disease, Major Depression, Bipolar Disorder, Schizophrenia, and Mild Cognitive Impairment, which is assumed to represent a transitional period before the development of AD. MiRNA target enrichment analysis of the selected 12 miRNAs indicated an involvement of miRNAs in nervous system development, neuron projection, neuron projection development, and neuron projection morphogenesis, respectively. Using this 12-miRNA signature we were able to differentiate between AD and controls with an accuracy of 93.3%, a specificity of 95.1%, and a sensitivity of 91.5%. The differentiation of AD from other neurological diseases was possible with accuracies between 73.8% and 77.8%. The differentiation of the other CNS disorders from controls yielded even higher accuracies. 

For more information on this study, visit here. 

Manuscripts citing this dataset 

• A blood based 12-miRNA signature of Alzheimer disease patients. 2013. DOI: https://doi.org/10.1186/gb-2013-14-7-r78 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed, and the dataset will be automatically delivered to your workspace Inbox upon approval.  

 Discuss 

Post a question or thought about this dataset here. 

A double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone on cognition in subjects with mild to moderate Alzheimer's disease

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Manuscripts citing this dataset 

• Clinical Study Report here. 
• Scientific Results Summary here. 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease 

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended-release tablets) in subjects with mild to moderate Alzheimer's Disease. 

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease 

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Manuscripts citing this dataset 

• Clinical Study Report here. 
• Scientific Results Summary here. 
• A double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone on cognition in subjects with mild to moderate Alzheimer's disease. Clinical Trial. Here. 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended-Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease

This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640. All subjects will receive rosiglitazone extended release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR. Subject participation will last until one of 5 conditions applies. After a 52-week open-label treatment phase, subjects will attend a final Follow-Up Visit 6 weeks after the end of treatment.

The primary objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD who have completed AVA105640. The secondary objective of this study is to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. 2011. DOI: 2174/156720511796391935

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended-Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease

This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672. All subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR as adjunctive therapy to their existing dose of acetylcholinesterase inhibitor. Subject participation will last until one of 5 conditions applies. After a 52-week open-label treatment phase, subjects will attend a final Follow-Up Visit 6 weeks after the end of treatment. The primary objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD who have completed either AVA102670 or AVA102672. The secondary objective of this study is to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. 2011. DOI: 2174/156720511796391935

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

An Open Label Single Oral Dose Study in Patients With Mild Alzheimer's Disease to Assess the Pharmacokinetics of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population

The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials. The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR) – 2016

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here. 

Discuss

Post a question or thought about this dataset here.

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease

The study is in subjects with Alzheimer's disease and evidence of cerebrovascular disease (CVD) who are currently treated with an acetylcholinesterase inhibitor (AChEI) and/or memantine. The study is a randomized, double-blind, placebo controlled, parallel group, repeat dose design, in which subjects (up to 60 randomized subjects per arm) will receive oral placebo or rilapladib (250 mg), once daily for 24 weeks in addition to their stable background AD therapy consisting of an acetylcholinesterase inhibitor (AChEI) and/or memantine. Subjects will take 250mg of rilapladib or placebo once daily for a period of 24 weeks. The total duration of participation for each subject will be approximately 30 weeks comprising approximately 4 weeks screening, 24 weeks treatment and 2 weeks follow-up. From the time of randomization and throughout the treatment period subjects will attend visits after 1 week, 4 weeks and thereafter every 4 weeks until Week 24. A follow-up visit will occur approximately 2 weeks after the final dose of study medication. Cognitive assessments will be performed at the screening visit, at the randomization (baseline) visit and at weeks 12 and 24 of the treatment period. Cerebrospinal fluid (CSF) samples will be taken via lumbar puncture at baseline and Week 24 for biomarker analyses related to Alzheimer's disease. Blood samples will be collected throughout the study for pharmacokinetics and a range of biomarker analyses. A range of safety and tolerability assessments will also be performed (including vital signs, laboratory tests, eye examinations and ECGs).

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease. 2015. DOI: https://doi.org/10.1016/j.trci.2015.06.003

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's.

This is a 16-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group design study in male and female subjects with mild to moderate Alzheimers disease (AD). Subjects will undergo 2-week placebo run-in period before randomisation. They will undergo weekly review of safety, tolerability and cognitive performance measures.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. 2014. DOI: 2174/1567205010666131212110148

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients with Alzheimer's Disease

A study to investigate the safety and tolerability of both single and multiple intravenous administration of GSK933776 in patients with Alzheimer's Disease.

Study Arms:

Experimental: Part A

Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimer’s Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo.

Experimental: Part B

Part B will be a single-blind, repeat dose, placebo-controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterize GSK933776 fully. Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. 2015. DOI: https://doi.org/10.1371/journal.pone.0098153

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

A reference induced pluripotent stem cell line for large-scale collaborative studies 

This study deep characterized widely available induced pluripotent stem cell (iPSC) lines to rationally select a line that performs well in multiple experimental approaches. We performed an analysis of transcriptional patterns in the pluripotent state, whole genome sequencing, genomic stability after highly efficient CRISPR-mediated gene editing, integrity of the p53 pathway, and differentiation efficiency towards multiple lineages and identified KOLF2.1J as a well-performing cell line. Here, we provide the whole genome and single cell RNA sequencing files from our analyses. 

The associated Github for these files can be found at https://github.com/NIH-CARD/INDI-README/tree/main/INDI-genetics. 

Manuscripts citing this dataset 

• A reference induced pluripotent stem cell line for large-scale collaborative studies. 2021. DOI: https://doi.org/10.1101/2021.12.15.472643 
• Infrastructural expectations: exploring the promise of international large-scale induced pluripotent stem cell Banks. 2017. DOI: https://doi.org/10.1080/14636778.2017.1289470 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed, and the dataset will be automatically delivered to your workspace Inbox upon approval.  

Discuss 

Post a question or thought about this dataset here. 

A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist

This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimer's disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated dose in the patients.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. 2013. DOI: 2174/1567205011310030003

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

A Study of Semagacestat for Alzheimer's Patients

The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment. Baseline for the efficacy measures is defined as the baseline for feeder studies LFAN (NCT00594568) and LFBC (NCT00762411). For all safety analyses (adverse events), baseline for patients will be week 0 of this study (LFBF). Preliminary results from LFAN and LFBC showed semagacestat did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Study drug was stopped in all studies. Studies LFAN, LFBC and LFBF have been amended to continue collecting safety data, including cognitive scores, for at least seven months. The CT-Registry will reflect results of analyses from the original protocol in addition to those from the amended protocol. Very few participants from LFBC rolled over into LFBF (N = 9). Due to insufficient sample size, the data for LFBC participants who rolled into LFBF were not analyzed.

Manuscripts citing this dataset

• Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease. 2009. DOI: https://doi.org/10.1517/14656560903044982
• REVIEW: γ‐Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. 2010. DOI: https://doi.org/10.1111/j.1755-5949.2010.00164.x
• A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. 2013. DOI: 1056/NEJMoa1210951

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

AD Synthetic Patient Data 

A synthetic dataset based on the Critical Path for Alzheimer's Disease (CPAD) collection of patient data from control arms of clinical trials for Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). The data for this preliminary study was extracted from the Critical Path Institute Online Data Repository (CODR). 

Manuscripts citing this dataset 

• Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer’s Disease. 2022. DOI: 10.3233/JAD-215553 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed, and the dataset will be automatically delivered to your workspace Inbox upon approval.  

Discuss 

Post a question or thought about this dataset here. 

Alzheimer's Disease and Healthy Aging Data

The Alzheimer’s Disease and Healthy Aging Data provides access to national and state level CDC data on a range of key indicators of health and well-being for older adults, including: Caregiving, Subjective Cognitive Decline, Screenings and vaccinations, and Mental health. These indicators provide a snapshot of currently available surveillance information and can be useful for prioritization and evaluation of public health interventions.

Visit this site for more information: https://chronicdata.cdc.gov/Healthy-Aging/Alzheimer-s-Disease-and-Healthy-Aging-Data/hfr9-rurv

Manuscripts citing this dataset

• https://www.cdc.gov/aging/pdf/State-Aging-Health-in-America-2013.pdf
• https://www.cdc.gov/aging/pdf/2018-2023-Road-Map-508.pdf
• https://www.cdc.gov/aging/data/pdf/Aggregated-2017-caregiving-h.pdf
• https://www.cdc.gov/aging/data/pdf/Aggregated-2016-Cognitive-Infographic-508.pdf

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer. 

Data Use Agreement

None specified

Publishing results using this dataset?

The dataset owner has specified no requirements when publishing results using this dataset.

Discuss

Post a question or thought about this dataset here.

Alzheimer's Prevention Virtual Cohort

A synthetic dataset of pre-clinical dementia patients, generated using privacy-preserving generative deep learning techniques, based on the EPAD LCS V1500.0 dataset. As well as benchmarking against a series of statistical fidelity and privacy preserving measures, amyloid beta positivity was used as a test of how comparable the dataset is for predictive tasks and model. Contains 125,000 synthetic records.

More information on the synthesis process is available in the paper Virtual Cohorts and Synthetic Data in Dementia: An Illustration of Their Potential to Advance Research

Manuscripts citing this dataset

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165312/
• https://alzres.biomedcentral.com/articles/10.1186/s13195-019-0576-y

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved, and the dataset will be delivered to your workspace Inbox upon user-initiated transfer. 

Data Use Agreement

None specified

Publishing results using this dataset?

The dataset owner has specified no requirements when publishing results using this dataset.

Discuss

Post a question or thought about this dataset here.

BLSA Open Data

What is it and what does it include? 

The National Institute on Aging’s Baltimore Longitudinal Study of Aging (BLSA) is America's longest-running scientific study of human aging. It began in 1958; today, the BLSA is world-renowned, having generated thousands of scientific papers and having made major contributions to our understanding of what it means to get older. The study includes more than 1,300 male and female BLSA participants ranging in age from their twenties to 100s, who come regularly for a variety of tests to help scientists observe changes over years of life. BLSA data available on the ADDI platform are a subset of the available measures and records that are designated as being open for public use by both the participants and the study. 

How can I use this dataset to advance my research? 

This dataset is ideal if: 

• you’re interested in studying longitudinal physical and cognitive changes that define aging.  
• you’re interested in identifying genetic, physical, behavioral, and environmental factors that affect the rate of change in these traits.  
• you’re looking to understand the interrelationship between aging and chronic disease and other conditions, and their independent and joint impact on age-related decline. 

Has this dataset helped researchers understand Alzheimer’s and other dementias better? 

Of course!  

• AD & Personality: 

In 2021, researchers aimed to examine whether personality traits are associated with amyloid and tau neuropathology in a new sample and meta-analyses. Their research showed that among cognitively normal BLSA participants, neuroticism was associated with higher cortical amyloid burden, and conscientiousness was associated with lower cortical amyloid burden. These associations remained significant after accounting for age, sex, education, depressive symptoms, hippocampal volume, and APOE ε4. By aggregating results across samples, this study advances knowledge on the association between personality and neuropathology. Neuroticism and conscientiousness may contribute to resistance against amyloid and tau neuropathology. September 2021  – DOI: 10.1016/j.biopsych.2021.08.021 

• AD & mitochondrial energetics: 

In 2022, researchers aimed to study whether mitochondrial dysfunction predicts subsequent mobility decline. After examining 380 cognitively normal participants aged 60 and older who were well-functioning and free of Parkinson's disease and stroke at baseline, they found that among initially well-functioning older adults, worse muscle mitochondrial function predicts mobility decline, and part of this longitudinal association is explained by decline in muscle strength and mass. Their findings suggest that worse mitochondrial function contributes to mobility decline with aging. These findings need to be verified in studies correlating longitudinal changes in mitochondrial function, muscle, and mobility performance. January 2022 – DOI: 10.1111/acel.13552 

Manuscripts citing this dataset 

• The BLSA has generated hundreds of scientific papers and made major contributions to our understanding of aging and the aging process. On this page, you can explore BLSA publications from 1982 to the present: publications. 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Once you have submitted your access request, your application will be reviewed by the BLSA team. Once your access has been provisioned you will receive an email with instructions for federated access including a link to access your API token. For a quick explanation on what is federated data and how to access it, see this video. 

Data Use Agreement 

Please refer to the BLSA Data Sharing Schedules, Processes and Required Agreements here. 

Publishing results using this dataset? 

The dataset owner has specified no requirements when publishing results using this dataset. 

Discuss 

Post a question or thought about this dataset here. 

BLSA Synthetic Data

What is it and what does it include?

This dataset represents SYNTHETIC data generated off of the real data collected by The National Institute on Aging’s Baltimore Longitudinal Study of Aging (BLSA). It is useful for getting familiar with the BLSA data and determining whether the study houses measures of interest for your research and helping to preparing an analysis proposal; results analyses are NOT publishable in any form since the data is not real. Visit the related BLSA OPEN Data project on the AD Workbench to find related real BLSA data designated as publicly available.

How can I use this dataset to advance my research?

This dataset is ideal if:

• you’re interested in studying longitudinal physical and cognitive changes that define aging.
• you’re interested in identifying genetic, physical, behavioral, and environmental factors that affect the rate of change in these traits.
• you’re looking to understand the interrelationship between aging and chronic disease and other conditions, and their independent and joint impact on age-related decline.

 

Has this dataset helped researchers understand Alzheimer’s and other dementias better?

Of course!

• AD & Personality:

In 2021, researchers aimed to examine whether personality traits are associated with amyloid and tau neuropathology in a new sample and meta-analyses. Their research showed that among cognitively normal BLSA participants, neuroticism was associated with higher cortical amyloid burden, and conscientiousness was associated with lower cortical amyloid burden. These associations remained significant after accounting for age, sex, education, depressive symptoms, hippocampal volume, and APOE ε4. By aggregating results across samples, this study advances knowledge on the association between personality and neuropathology. Neuroticism and conscientiousness may contribute to resistance against amyloid and tau neuropathology. September 2021  – DOI: 10.1016/j.biopsych.2021.08.021

• AD & mitochondrial energetics:

In 2022, researchers aimed to study whether mitochondrial dysfunction predicts subsequent mobility decline. After examining 380 cognitively normal participants aged 60 and older who were well-functioning and free of Parkinson's disease and stroke at baseline, they found that among initially well-functioning older adults, worse muscle mitochondrial function predicts mobility decline, and part of this longitudinal association is explained by decline in muscle strength and mass. Their findings suggest that worse mitochondrial function contributes to mobility decline with aging. These findings need to be verified in studies correlating longitudinal changes in mitochondrial function, muscle, and mobility performance. January 2022 – DOI: 10.1111/acel.13552

Manuscripts citing this dataset

• The BLSA has generated hundreds of scientific papers and made major contributions to our understanding of aging and the aging process. On this page, you can explore BLSA publications from 1982 to the present: publications.

Request access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved upon which the dataset will be ready to be manually transferred into your workspace inbox

Data Use Agreement

Please refer to the BLSA Data Sharing Schedules, Processes and Required Agreements here.

Publishing results using this dataset?

The dataset owner has specified no requirements when publishing results using this dataset.

Discuss

Post a question or thought about this dataset here.

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease 

This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD). 

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Manuscripts citing this dataset 

• A multi-center randomized proof-of-concept clinical trial applying [¹⁸F] FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. 2010. DOI: 10.3233/JAD-2010-100939 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

Critical Path for Alzheimer's Disease (CPAD) Database

Patient-level, control-arm data from multiple aggregated studies of AD and MCI. The database contains, but is not limited to, demographic information, APOE4 genotype, concomitant medications, and cognitive scales (MMSE and ADAS-Cog). All data has been remapped to a common data standard such that all the data can be analyzed across all studies. It is available to CPAD consortium members, and to external qualified researchers who submit, and are approved for, a request for access. All data are fully de-identified. Data was originally mapped to SDTM and converted to a relational database.

To learn more, visit the Critical Path Institute’s overview of this data set here.

Manuscripts citing this dataset

• The Critical Path for Alzheimer’s Disease (CPAD) Consortium: A platform for pre-competitive data sharing, standardization, and analysis to support quantitative tools for AD drug development. 2021. DOI: https://doi.org/10.1002/alz.051903
• DRAFT Qualification opinion for Prognostic Covariate Adjustment (PROCOVA). 2022. https://www.ema.europa.eu/en/documents/other/draft-qualification-opinion-prognostic-covariate-adjustment-procovatm_en.pdf
• Effective Data Sharing as a Conduit for Advancing Medical Product Development. 2021. DOI: 1007/s43441-020-00255-8
• Open Data Revolution in Clinical Research: Opportunities and Challenges. DOI: https://doi.org/10.1111/cts.12756
• Technologies for Measuring Cognition in Clinical Trials. https://isctm.org/public_access/Autumn2018/Presentation/Arneric-Aut18.pdf
• Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments. 2018. DOI: https://doi.org/10.1016/j.bcp.2018.01.043
• Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease. A Meta-analysis. 2017. DOI: 1001/jamaneurol.2017.2188
• Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem. 2017. DOI: https://doi.org/10.1038/nrd.2017.153

Detection of Alzheimer’s Disease at Mild Cognitive Impairment and Disease Progression Using Autoantibodies as Blood-based Biomarkers - GSE74763 

Human serum samples from Alzheimer's disease driven mild cognitive impairment and non-diseased controls were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. Other neurodegenerative and non-neurodegenerative diseases were also used to help measure the specificity of the selected biomarkers. 

In the study presented here, 50 Alzheimer's disease driven mild cognitive impairment samples and 50 control human serum samples were probed onto human protein microarrays in order to identify differentially expressed autoantibodies. Microarray data was analyzed using several statistical significance algorithms, and autoantibodies that demonstrated significant differences in group prevelance were selected as potential biomarkers of disease. Prediction classification analysis using Invitrogen's Prospector v5.2.1 and Random Forest tested the diagnostic efficacy of the identified biomarkers. Differentiation of mild cognitive impairment samples from other neurodegenerative and non-neurodegenerative controls (Parkinson's disease, multiple sclerosis, and *** cancer) assessed the specificity of the selected biomarkers, while comparison with mild-moderate Alzheimer's disease samples assessed their utility for use in disease staging.  

For more information on this study, visit here. 

Manuscripts citing this dataset 

• Diagnostic AI Modeling and Pseudo Time Series Profiling of AD and PD Based on Individualized Serum Proteome Data. 2021. DOI: https://doi.org/10.3389/fbinf.2021.76 
• Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. 2016. DOI: https://doi.org/10.1016/j.dadm.2016.03.002 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed, and the dataset will be automatically delivered to your workspace Inbox upon approval.   

Discuss 

Post a question or thought about this dataset here. 

DPUK Synthetic Dataset

Data from three population cohorts were used to create a synthetic dataset (synth1.0) for system development, methods development and training purposes. The synthetic dataset does not contain any personally identifiable information.

Variables were selected to represent those typically used in dementia research and to cover survey, biomarker and imaging data modalities. Sixty-one variables were modelled, to these was added a unique participant identifier resulting in a dataset of 62 variables. Variable distributions and covariance from the source cohorts were used to parameterize the model. Generated data were checked for range, distributions, and associations. The generated dataset comprised 150,618 individuals.

To learn more, visit the DPUK Cohort Directory here.

Manuscripts citing this dataset

• Machine learning for the life-time risk prediction of Alzheimer’s disease: a systematic review. 2021. DOI: https://doi.org/10.1093/braincomms/fcab246
• Global dialogue on data sharing for dementia research: Transcript The dementia landscape Project. World Dementia Council. 2021. https://www.worlddementiacouncil.org/sites/default/files/2021-06/DLP%20-%20Transcript%20-%20Data.pdf
• International Population Data Linkage Network 2018 Conference. 2018. https://ipdln.org/sites/default/files/2018ConcurrentSessions/AT-A-GLANCE-Final.pdf

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the DPUK team and the dataset will be automatically delivered to your workspace Inbox upon approval. 

More information on DPUK’s data access policy can be found here.

Data Use Agreement

Information on DPUK’s data management and use can be found here. The cohort metadata access agreement can be found here.

Publishing results using this dataset?

 DPUK asks that any publication of the metadata must acknowledge the use of DPUK resources including the source data. For detailed information on how to acknowledge DPUK’s data correctly, visit here.

Discuss

Post a question or thought about this dataset here.

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

The purposes of this study are to determine:

• The safety of LY450139 dihydrate and any side effects that might be associated with it.
• How much LY450139 dihydrate should be given and how long it may be detected in blood.
• To determine if LY450139 dihydrate may have an effect on a protein found in blood, called A beta. This protein is studied in subjects with Alzheimer's disease.
• To collect and store samples from blood and spinal fluid for research related to Alzheimer's disease and similar (neurodegenerative) diseases or inflammation (irritation) that may provide information on how subjects respond to LY450139 or other medications.

Length of study: Approximately 29 weeks.

Number of office visits: 11 for most subjects: initial visit, every other week during 14 weeks of study drug treatment, and 2 follow-up visits.

At no cost, approximately 45 eligible participants will receive:

• Study medication
• Study-related diagnostic and laboratory evaluations Keywords

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. 2008. DOI: 1001/archneur.65.8.1031
• A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. 2010. DOI: https://doi.org/10.1186/alzrt30

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

Effect of LY450139 on the Long-Term Progression of Alzheimer's Disease

Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid (β-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD patients are required to have these amyloid plaques in the brain in order to have a definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (γ-secretase) lowers the production of β-amyloid. Semagacestat (LY450139) is a functional γ-secretase inhibitor and was shown to lower β-amyloid in blood and spinal fluid in humans tested thus far and in blood, spinal fluid, and brain in animals tested thus far. This study used several different tests to measure the effect of semagacestat on both β-amyloid and amyloid plaques for some participants. The build-up of amyloid plaques was measured by a brain scan that takes a picture of amyloid plaques in the brain. Other tests measured the overall function of the brain and brain size in some participants. In this trial, participants who initially received placebo (inactive sugar pill) were, at a certain point in the study, switched over to active drug, semagacestat. In other words, all participants could eventually receive active drug. Participation could last approximately 2 years. Participants taking approved AD medications were permitted to participate in this study and continue taking these medications during the study. All participants who completed this study had the option to continue receiving semagacestat by participating in an open-label study.

Preliminary results from this study (H6L-MC-LFAN [LFAN]) and another similar study (H6L-MC-LFBC [LFBC; NCT00762411]) showed semagacestat did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Study drug was stopped in all studies. Studies LFAN, LFBC, and open-label H6L-MC-LFBF (LFBF; NCT01035138) were amended to continue collecting safety data, including cognitive scores, for at least 7 months. The Clinical Trial Registry (CTR) will reflect results of analyses from the original LFAN protocol in addition to those from the amended LFAN protocol.

Manuscripts citing this dataset

• Clinical trial. Effect of LY450139 on the Long-Term Progression of Alzheimer's Disease. 2008. https://clinicaltrials.gov/ct2/show/NCT00594568
• Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. 2015. DOI: 3233/JAD-142508
• Alzheimer's disease progression by geographical region in a clinical trial setting. 2015. DOI: https://doi.org/10.1186/s13195-015-0127-0
• Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease. 2015. DOI: https://doi.org/10.1186/s13195-015-0121-6
• A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. 2013. DOI: 1056/NEJMoa1210951

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

Effects of LY450139, on the Progression of Alzheimer's Disease as Compared with Placebo

Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta amyloid (β-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD patients are required to have these amyloid plaques in the brain in order to have a definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (γ-secretase) lowers the production of β-amyloid. Semagacestat (LY450139) is a functional γ-secretase inhibitor and was shown to lower β-amyloid in blood and spinal fluid in humans tested thus far and in blood, spinal fluid and brain in animals tested thus far. This study used several different tests to measure the effect of semagacestat on both β-amyloid and amyloid plaques for some patients. The buildup of amyloid plaques was measured by a brain scan that takes a picture of amyloid plaques in the brain. Other tests measured the overall function of the brain and brain size in some patients. In this trial, patients who initially received placebo (inactive sugar pill) were, at a certain point in the study, switched over to active drug, semagacestat. In other words, all patients could eventually receive active drug. Each patient's participation could last approximately 2 years. Patients taking approved AD medications were permitted to participate in this study and continue taking these medications during the study. All patients who completed this study had the option to continue receiving semagacestat by participating in an open label study.

Preliminary results from this study (LFBC) (and another similar study LFAN [NCT00594568]) showed semagacestat did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Study drug was stopped in all studies. LFBC, LFAN and open label LFBF (NCT01035138) have been amended to continue collecting safety data, including cognitive scores, for at least seven months. The CT-Registry will reflect results of analyses from the original protocol in addition to those from the amended protocol.

Manuscripts citing this dataset

• Alzheimer's disease progression by geographical region in a clinical trial setting. 2015. DOI: https://doi.org/10.1186/s13195-015-0127-0
• Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. 2015. DOI: 3233/JAD-142508

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

The English Longitudinal Study of Ageing

The primary objective of the English Longitudinal Study of Ageing (ELSA) is to collect longitudinal multidisciplinary data from a representative sample of the English population aged 50 to 100 at recruitment. ELSA was developed as a companion study to the Health and Retirement Study (HRS) in the USA and documents the experience of growing old in England in the 21st century. The study collects both objective and subjective data relating to health and disability, biological markers of disease, economic circumstance, social participation, networks and well-being.

To learn more, visit the English Longitudinal Study of Ageing here.

Manuscripts citing this dataset

• Sex differences in functional limitations and the role of socioeconomic factors: a multi-cohort analysis. 2021. DOI: https://doi.org/10.1016/S2666-7568(21)00249-X
• The prevalence and associated mortality of non-anemic iron deficiency in older adults: a 14 years observational cohort study. 2020. DOI: https://doi.org/10.1111/bjh.16409
• Personality and Dementia Risk in England and Australia. 2020. DOI: https://doi.org/10.1024/1662-9647/a000241
• The long-term effects of a polygenetic predisposition to general cognition on healthy cognitive ageing: evidence from the English Longitudinal Study of Ageing. 2022. DOI: https://doi.org/10.1017/S0033291721004827

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the DPUK team and the dataset will be automatically delivered to your workspace Inbox upon approval. 

Data Use Agreement

Visit the user guides here.

Publishing results using this dataset?

 For detailed information on how to cite ELSA’s data, visit their citation guide here.

Discuss

Post a question or thought about this dataset here.

EPAD LCS v.IMI

A key achievement of the European Prevention of Alzheimer's Dementia (EPAD) project (http://ep-ad.org/) was the establishment of a Longitudinal Cohort Study (LCS) that has screened a total of 2,096 participants from 31 study sites in 10 European countries. A wide range of cognitive, clinical, neuroimaging, and biomarker data were collected, thus generating a comprehensive and large data set to help further our understanding of the early stages of Alzheimer’s disease. The LCS was initiated and the first participant screened in May 2016. Screening into the LCS was stopped on 29 February 2020. The final dataset presented here is called Version.IMI (V.IMI) as it represents all the data collected and processed during the period the project was funded by the Innovative Medicines Initiative (IMI) (https://www.imi.europa.eu/).

Following approval to access EPAD data, the user can transfer the v.IMI files to their workspace. Genomic data files however are not accessed in the same way. The EPAD Genomics Shared Drive will be linked to the user’s Workspace Virtual Machine by Aridhia in the background.

Genome-wide genotyping was performed on 1,983 participant samples assaying 713,127 SNPs across the autosomes. PLINK-formatted files of pre-QC’d data are available, as are subsets of the data filtered for quality, ancestry and relatedness. Pairwise relatedness was calculated across all participants and the relatedness table is available. Finally, three independent imputation analyses were performed using the HRC, 1000Genomes and TOPMed imputation panels, respectively. Please see the files in the Resources section for more details on the genomics data.

Manuscripts citing this dataset

https://www.cambridge.org/core/books/alzheimers-disease-drug-development/02D6344BA56336D0E0E40C68B19C7C3F

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the EPAD team and the dataset will be automatically delivered to your workspace Inbox upon approval. The EPAD dataset includes clinical data, images, and genomics data. To access the genomics data, please refer to the Accessing Data from Read-only Drive tech help article. Biological samples are also requestable via ADDI.

Data Use Agreement

The dataset terms of usage can be accessed here.

Publishing results using this dataset?

The dataset owner has specified that when publishing results using this dataset, EPAD and their funders are acknowledged. The requirements can be accessed here.

Discuss

Post a question or thought about this dataset here.

EPAD LCS v500.0

Please note that a more recent version of these data can be found in the EPAD LCS v.IMI dataset.

European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study (LCS) V500.0 data release. https://doi.org/10.34688/epadlcs_v500.0_19.05.10

To learn more about this dataset, visit the Data Information Pack here.

Manuscripts citing this dataset

• Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study. 2020. DOI: 1186/s13195-020-00711-5
• Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. 2020. DOI: https://doi.org/10.1186/s13195-019-0576-y
• The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0. 2020. DOI: 14283/jpad.2019.46
• Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort. 2020. DOI: 3233/JAD-200514

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the EPAD team and the dataset will be automatically delivered to your workspace Inbox upon approval. Biological samples are also requestable via ADDI.

Data Use Agreement

The dataset terms of usage can be accessed here.

Publishing results using this dataset?

The dataset owner has specified that when publishing results using this dataset, EPAD and their funders are acknowledged. The specifications on how to provide the correct acknowledgement can be found here.

For a more in detail outline on EPAD’s policies for publication and publication credits, see EPAD Policy for publication here.

Discuss

Post a question or thought about this dataset here.

EPAD LCS v500.1

Please note that a more recent version of these data can be found in the EPAD LCS v.IMI dataset.

European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study (LCS) V500.1 data release. https://doi.org/10.34688/epadlcs_v500.1_20.04.29

To learn more about this dataset, visit the Data Information Pack here.

Manuscripts citing this dataset

• Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study. 2020. DOI: 1186/s13195-020-00711-5
• Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. 2020. DOI: https://doi.org/10.1186/s13195-019-0576-y

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the EPAD team and the dataset will be automatically delivered to your workspace Inbox upon approval. Biological samples are also requestable via ADDI.

Data Use Agreement

The dataset terms of usage can be accessed here.

Publishing results using this dataset?

The dataset owner has specified that when publishing results using this dataset, EPAD and their funders are acknowledged. The specifications on how to provide the correct acknowledgement can be found here.

For a more in detail outline on EPAD’s policies for publication and publication credits, see EPAD Policy for publication here.

Discuss

Post a question or thought about this dataset here.

EPAD LCS v1500.0

Please note that a more recent version of these data can be found in the EPAD LCS v.IMI dataset.

European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study (LCS) V1500.0 data release. https://doi.org/10.34688/epadlcs_v1500.0_19.11.29

To learn more about this dataset, visit the Data Information Pack here.

Manuscripts citing this dataset

• Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study. 2020. DOI: 1186/s13195-020-00711-5
• Virtual Cohorts and Synthetic Data in Dementia: An Illustration of Their Potential to Advance Research. 2020. DOI: 3389/frai.2021.613956
• The role of dysfunctional beliefs and attitudes about sleep in the association between daily sleep and affect in adolescents and emerging adults. 2021. DOI: https://doi.org/10.1093/sleepadvances/zpab014.009

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the EPAD team and the dataset will be automatically delivered to your workspace Inbox upon approval. Biological samples are also requestable via ADDI.

Data Use Agreement

The dataset terms of usage can be accessed here.

Publishing results using this dataset?

The dataset owner has specified that when publishing results using this dataset, EPAD and their funders are acknowledged. The specifications on how to provide the correct acknowledgement can be found here.

For a more in detail outline on EPAD’s policies for publication and publication credits, see EPAD Policy for publication here.

Discuss

Post a question or thought about this dataset here..

The GERAS Study - EU

GERAS is an 18-month, multicentre, prospective, non-interventional cohort study conducted in France, Germany, and the UK, designed to evaluate the costs and resource use associated with AD dementia for community-dwelling patients and their caregivers. Participants were enrolled between October 2010 and September 2011. Inclusion criteria were community-dwelling patients, aged at least 55 years, presenting within the normal course of clinical care, diagnosed with probable AD dementia according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria, with a Mini-Mental State Examination (MMSE) score of ≤26 points, and with an informal caregiver who was willing to participate in the study and undertake responsibility for the patient for at least 6 months of the year. Information was collected for patients and caregivers at the baseline visit and at 6, 12, and 18 months during routine care visits. Data collected included sociodemographic, comorbidities, medications, and health-related quality of life. Additional patient assessments included cognitive function (assessed using the MMSE and the cognitive subscale of the Alzheimer’s Disease Assessment Scale [ADAScog]), functional ability (assessed using the Alzheimer’s Disease Co-operative Study Activities of Daily Living Inventory [ADCS-ADL]), and behavioural and psychological symptoms (assessed using the Neuropsychiatric Inventory [NPI]). Caregivers also completed the Zarit Burden Interview (ZBI), which provides a measure of caregiver burden. Overall, 1,497 patients with AD dementia were enrolled into the study across the three MMSE severity domains Mild (MMSE 21-26; n=567), Moderate (MMSE 15-20; n=472) and Moderate/Severe (MMSE < 15; n=458), mean age 77.6 years; 55% female; with a mean time from diagnosis of 2.2 years.

Manuscripts citing this dataset

• The Humanistic and Economic Burden of Alzheimer's Disease. 2022. DOI: https://doi.org/10.1007/s40120-022-00335-x
• Resource utilization, costs and clinical outcomes in non-institutionalized patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study. 2016. DOI: https://doi.org/10.1186/s12877-016-0371-6
• The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings. 2013. DOI: 3233/JAD-122392

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer. 

Data Use Agreement

More information on data access and use policies established by the trial sponsor can be found here.

Publishing results using this dataset?

The sponsor of this trial, Eli Lilly & Company, states their publication policy here.

Discuss

Post a question or thought about this dataset here.

The GERAS Study - Japan

GERAS Japan was an 18-month, prospective, multicenter, longitudinal, observational study conducted in 30 sites in different regions in Japan, designed to evaluate the costs and resource use associated with AD dementia for community-dwelling patients and their caregivers. Participants were enrolled from November 2016 to December 2017. Eligible patients were males and females aged ≥55 years old, who had received a diagnosis of probable AD according to the National Institute on Aging and Alzheimer’s Association and with a Mini-Mental State Examination (MMSE) score of 26 or less. At baseline, patients were stratified into groups based on AD severity (mild: MMSE 21-26, moderate: MMSE 15-20, and moderately severe/severe [MS/S]: MMSE < 15). Healthcare resource utilization and caregiver burden were assessed using the Resource Utilization in Dementia and Zarit “Caregiver” Burden Interview questionnaires, respectively. Total monthly societal costs were estimated using Japan-specific unit costs of services and products (patient direct healthcare use, patient social care use, and informal caregiving time). Overall, 553 patients (156 mild; 209 moderate; 188 MS/S) were enrolled with mean age 80.3 years, 73% female.

Manuscripts citing this dataset

• Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study. 2020. DOI: 3233/JAD-190811
• Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study. 2021. DOI: https://doi.org/10.1080/03007995.2021.1922369
• Increase in direct social care costs of Alzheimer's disease in Japan depending on dementia severity. 2021. DOI: https://doi.org/10.1080/03007995.2021.1922369
• Gender’s Effects to the Early Symptoms of Alzheimer’s Disease in 5 Asian Countries. DOI: https://doi.org/10.1177/1533317517698796

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer. 

Data Use Agreement

More information on data access and use policies established by the trial sponsor can be found here.

Publishing results using this dataset?

The sponsor of this trial, Eli Lilly & Company, states their publication policy here.

Discuss

Post a question or thought about this dataset here.

The GERAS II Study

The GERAS II study was a prospective, multicenter, observational study that aimed to assess societal costs and resource use associated with AD among patients and their primary caregivers in Italy and Spain. Eligible patients were males and females aged ≥55 years old, who had received a diagnosis of probable AD according to the National Institute on Aging and Alzheimer’s Association and with a Mini-Mental State Examination (MMSE) score of 26 or less. At baseline, patients were stratified into groups based on AD severity as measured through their MMSE score (mild: MMSE 21-26, moderate: MMSE 15-20, and moderately severe/severe [MS/S]: MMSE < 15). Data collected for patients and caregivers included demographics/clinical characteristics; current medication; patient cognitive, functional and behavioral assessments; patient and caregiver health-related quality of life (HRQoL); and patient and caregiver resource use. The costs associated with the resources used were calculated. Costs were broken down into patient healthcare costs, patient social care costs and caregiver informal care costs. In Italy, 198 patients (29 mild; 80 moderate; 89 MS/S) were enrolled with mean age at baseline 77.5 years, 60% female. In Spain, a total of 380 participants (116 mild; 118 moderate; 146 MS/S) were enrolled with mean age 75.7 years, 63% female.

Manuscripts citing this dataset

• Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study. 2017. DOI: https://doi.org/10.1017/S1041610217001211
• The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings. 2013. DOI: 3233/JAD-122392

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer. 

Data Use Agreement

More information on data access and use policies established by the trial sponsor can be found here.

Publishing results using this dataset?

The sponsor of this trial, Eli Lilly & Company, states their publication policy here.

Discuss

Post a question or thought about this dataset here.

The GERAS Study - US

The GERAS Study - US was a prospective, multicenter, observational study that aimed to assess societal costs and resource use associated with AD among patients and their primary caregivers across 76 sites in the United States. Eligible patients were between the ages of 55 and 85 years at baseline, met criteria for early AD in the opinion of the enrolling physician, had Mini-Mental State Examination (MMSE) scores ≥20 and had study partners who were willing to participate. Participants were classified as mildly cognitively impaired ([MCI]; MMSE score 24-30 and Functional Activities Questionnaire [FAQ] <6) or MILD (mild dementia; MMSE 20-30 and FAQ ≥6). Subsequent stages further classified participants as either amyloid positive or negative. Data collected for patients and caregivers included demographics/clinical characteristics; current medication; patient cognitive, functional and behavioral assessments; patient and caregiver health-related quality of life (HRQoL); and patient and caregiver resource use. The costs associated with the resources used were calculated. Costs were broken down into patient healthcare costs, patient social care costs and caregiver informal care costs. A total of 1,198 patients were evaluated (300 MCI amyloid positive, 281 MCI amyloid negative, 317 MILD amyloid positive, 300 MILD amyloid negative). Overall, patients had a mean age of 70.4 years with a slight preponderance of females (55.3%).

To learn more about this clinical trial, visit the study record detail here.

To explore the data further, visit GAAIN: https://www.gaaindata.org/partner/GERAS

Manuscripts citing this dataset

• The Humanistic and Economic Burden of Alzheimer's Disease. 2022. DOI: https://doi.org/10.1007/s40120-022-00335-x
• Disease progression and costs at 3-year follow-up of GERAS-US: A 3-year study of mild cognitive impairment and mild dementia due to Alzheimer’s disease in the United States. 2021. DOI: https://doi.org/10.1002/alz.057473

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are automatically approved and the dataset will be delivered to your workspace Inbox upon user-initiated transfer. 

Data Use Agreement

More information on data access and use policies established by the trial sponsor can be found here.

Publishing results using this dataset?

The sponsor of this trial, Eli Lilly & Company, states their publication policy here.

Discuss

Post a question or thought about this dataset here.

Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients with Mild Alzheimer's Disease or Mild Cognitive Impairment

This is a phase I, an open label, single dose, and parallel group study to assess short term pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of GSK933776 by i.v. administration.

For more information on this study, visit the Study Record Detail of the respective clinical trial here.

Manuscripts citing this dataset

• Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study. 2014. DOI: https://doi.org/10.1186/alzrt249
• First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. 2015. DOI: https://doi.org/10.1371/journal.pone.0098153

Request access

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.

Data Use Agreement

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.

Publishing results using this dataset?

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.

Discuss

Post a question or thought about this dataset here.

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease 

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended-release tablets) in subjects with mild to moderate Alzheimer's Disease.

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis - GSE90828 

Mild cognitive impairment (MCI) is an intermediate state between normal aging, and Alzheimer’s disease, and other dementias. Early detection of dementia, and MCI, is a crucial issue in terms of secondary prevention. Blood biomarker detection is a possible way for early detection of MCI. Although disease biomarkers are detected by, in general, using single molecular analysis such as t-test, another possible approach is based on interaction between molecules. Results: Differential correlation analysis, which detects difference on correlation of two variables in case/control study, was carried out to the dataset with 745 microRNAs (miRNAs) from plasma samples of 30 age-matched controls and 23 MCI patients in Japan. The 20 pairs of miRNAs, which consist of 20 miRNAs, were selected as MCI markers. Two pairs of miRNAs (hsa-miR-191 and hsa-miR-101, and hsa-miR-103 and hsa-miR-222) out of 20 attained the highest area under the curve (AUC) value of 0.962 for MCI detection. Other two miRNA pairs that include hsa-miR-191 and hsa-miR-125b also attained high AUC value of ≥ 0.95. Pathway analysis was performed to the MCI markers for further understanding of biological implications. As a result, collapsed correlation on hsa-miR-191 and emerged correlation on hsa-miR-125b may have key role in MCI, and dementia progression. Conclusion: Differential correlation analysis, a bioinformatics tool to elucidate complicated and interdependent biological systems behind diseases, detects effective MCI markers that cannot be found by single molecule analysis such as t-test. 

To detect plasma miRNA biomarker for MCI, the blood samples were collected from 30 age-matched controls (Normal, 12 males and 18 females, mean age of 70.4) and 23 MCI patients (11 males and 12 females, mean age of 72.8). Total RNA was extracted from plasma using the miRNeasy Mini Kit (Qiagen). Then, the miRCURY LNA Universal RT microRNA PCR System, Ready-to-Use Human panel I and panel II, V2. were performed to profile miRNAs differential expression in these plasma samples. Processed data were compared between control and MCI groups. 

For more information on this study, visit here. 

Manuscripts citing this dataset 

• The Potential Role of miRNAs in Cognitive Frailty. 2021. DOI: https://doi.org/10.3389/fnagi.2021.763110 
• Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis. 2016. DOI: https://doi.org/10.1186/s40364-016-0076-1 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed, and the dataset will be automatically delivered to your workspace Inbox upon approval.  

Discuss 

Post a question or thought about this dataset here. 

PREVENT Dementia Research Programme

The PREVENT Dementia programme aims to identify the earliest signs of dementia, which may occur in the brain decades before symptoms appear. Participants were recruited in midlife (aged 40 – 59) to identify biological and psychological factors that may increase their risk of dementia in later life. Data available includes, MRI Imaging, cognition measures (COGNITO, 4 Mountains task, Visual short term memory binding task, supermarket trolley task), Lifestyle questionnaires (Diet, brain injury history, sleep, physical activity levels, education, history of traumatic life events).

Clinical data is also available including medical history, biometrics, APOE4 genetic status, GWAS data and samples are available for analysis on request. https://preventdementia.co.uk/

References

• https://www.tandfonline.com/doi/pdf/10.3109/09540261.2013.869195?casa_token=hR9P6QO-TNcAAAAA:m1OyWNH7Gs4fO6VPwnp5DP66oYonLA65Px55riOsg80finwUnjLo64CddFypaJq31TEE0zacoNXKyQ
• https://journals.sagepub.com/doi/full/10.1177/1471301218789307?casa_token=6eSGLCgLo6EAAAAA:1HcImXaIv96wfDqddY4p7-bCaq7BmBL8rHYC4sRubS4iXrnYyqd7Pj0qcN0t01697y_-GcBCsiVxcA
• https://jnnp.bmj.com/content/jnnp/91/2/158.full.pdf?casa_token=jyIut3TdX_UAAAAA:GDcx27m5vCv5Uz0i08jdbhu_FNBUrqE-eAfM-VeUxxLM-Ymn4fVqaAyEjHwrvAZQv3p9caBW2kMi

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the PREVENT team and the dataset will be automatically delivered to your workspace Inbox upon approval. Biological samples are also requestable via ADDI.

Data Use Agreement

The dataset terms of usage can be accessed here.

Publishing results using this dataset?

The dataset owner has specified that when publishing results using this dataset, PREVENT and their funders are acknowledged. The requirements can be accessed here.

Discuss

Post a question or thought about this dataset here.

RNAseq in Alzheimer's Disease patients - GSE53697 

Human brain samples were obtained from the Mount Sinai Brain Bank; RNA was Trizol extracted, Ribominus selected and submitted for high-throughput sequencing. 

Human brain samples from control and advanced Alzheimer's Diseased patients were subjected to RNAseq analysis to monitor RNA level changes during AD progression. Human brain samples from control and advanced Alzheimer's Diseased patients were subjected to RNAseq analysis to monitor RNA level changes during AD progression. 

For more information on this study, visit here. 

Request access 

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed, and the dataset will be automatically delivered to your workspace Inbox upon approval.   

Discuss 

Post a question or thought about this dataset here. 

Rosiglitazone (Extended-Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease 

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. 

This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with the currently approved AD medication, Aricept (donepezil). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects their response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene. 

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Manuscripts citing this dataset 

• Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. 2011. DOI: 10.2174/156720511796391935 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

Rosiglitazone (Extended-Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease 

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. 

This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects the response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene.

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Manuscripts citing this dataset 

• Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. 2011. DOI: 10.2174/156720511796391935 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

Rosiglitazone (Extended-Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease 

A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended-release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease. (REFLECT-1) 

Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose. RSG XR, the investigational drug, is an extended-release form of RSG. This study tests whether RSG XR safely provides benefit to people with mild to moderate Alzheimer's disease (AD). RSG XR is a new approach to AD therapy and this study tests whether one's genes alter the effectiveness of RSG XR. Glucose is used by cells to make energy that they need to live. Changes in the ability of cells to use of glucose can lead to diseases like diabetes. Glucose levels may be lower in the brains of AD patients, and their brain cells may also use glucose less well than in unaffected people. The proper function of brain cells may be critical to memory and thought. If brain cells use glucose poorly, this might impact AD. Drugs that help brain cells properly use glucose may help a person maintain normal memory and thinking. Data suggesting that RSG may help AD patients was first seen in a small study at the Univ. of Washington and then from a larger international GSK study. In the first study, those receiving RSG once daily for 6 months scored better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that benefited most from therapy with RSG XR had a specific genetic pattern. They lacked the gene that caused them to produce apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene from one parent. Subjects with one copy of the APOE e4 gene remained fairly stable while those with two copies of APOE e4 continued to worsen during the 6-month treatment. This study will directly test the effect of RSG XR on people who either have or lack the APOE e4 gene. 

For more information on this study, visit the Study Record Detail of the respective clinical trial here. 

Manuscripts citing this dataset 

• Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. 2010. DOI: https://doi.org/10.1159/000318845 

Request access 

Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.  

Data Use Agreement 

The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here. 

Publishing results using this dataset? 

Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.  

Discuss 

Post a question or thought about this dataset here. 

Synthetic EPAD Dataset

This synthetic dataset has been modeled after data from the European Prevention of Alzheimer's Dementia (EPAD) project (http://ep-ad.org/). The dataset consists of 10 tables and contains data for 200 subjects on biomarkers (apoe_synthetic, csf_synthetic), cognition (cdr_synthetic, dot_counting_synthetic, flanker_synthetic, four_mountains_synthetic, rbans_synthetic), socio demographics (socio_demographics_synthetic), vital signs (vital_signs_synthetic), and imaging (volumetric_synthetic).

The code used to generate the dataset can be found at https://github.com/aridhia/alzheimers-synthetic-data.

Manuscripts citing this dataset

• Virtual Cohorts and Synthetic Data in Dementia: An Illustration of Their Potential to Advance Research. 2020. DOI: 3389/frai.2021.613956
• Data preparation for artificial intelligence in medical imaging: A comprehensive guide to open-access platforms and tools. 2021. DOI: https://doi.org/10.1016/j.ejmp.2021.02.007

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are reviewed by the EPAD team and the dataset will be automatically delivered to your workspace Inbox upon approval. 

Data Use Agreement

The dataset terms of usage can be accessed here.

Publishing results using this dataset?

The dataset owner has specified that when publishing results using this dataset, EPAD and their funders are acknowledged. The specifications on how to provide the correct acknowledgement can be found here.

For a more in detail outline on EPAD’s policies for publication and publication credits, see EPAD Policy for publication here.

Discuss

Post a question or thought about this dataset here.

Whole-blood RNA seq data derived from C9orf72+FTD spectrum cases and controls

Preprint available on bioRxiv: Radiogenomics of C9orf72 expansion carriers reveals global transposable element de-repression and enables prediction of thalamic atrophy and clinical impairment

To learn more, visit the Whole-blood RNA-seq data derived from C9orf72+ FTD spectrum cases and controls here.

Request Access

Data access can be requested via AD Workbench FAIR portal here. Access requests are review and the dataset will be automatically delivered to your workspace Inbox upon approval. 

Discuss

Post a question or thought about this dataset here.